Copy of aggregated efficacy of Covid vaccines

	A	B	C	D	E	F	G	H	I	J	K
1		Johnson & Johnson	J&J control	Novavax	Novavax control	Ox/AZ	Ox/AZ control	Pfizer	Pfizer control	Moderna	Moderna control
2	Participants			7500	7500	5800	5800	21700	21700	15210	15210
3	Cases			6	56	37	112	8	162	11	185
4	Hospitalisations/severe disease			0	1	1	9	1	9	0	29
5	Deaths			0	0	0	1	0	0	0	1
6
7		All vaccines	all controls	% efficacy (central estimate)	95% CI
8	Participants	50210	50210
9	Cases	62	515	88%	91%, 84%
10	Of which mild/moderate	60	465	87%	90%, 83%
11	Hospitalisations/severe disease (including deaths)	2	50	96	99%, 84%
12	Deaths	0	2	100	N/A
13
14
15	References	J&J	Novavax	Ox/AZ	Pfizer	Moderna
16		https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial	https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932661-1	https://www.nejm.org/doi/full/10.1056/NEJMoa2034577	https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100